Breaking News
Get 40% Off 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolio
Close

TriSalus Life Sciences Inc (TLSI)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow TriSalus Life Sciences's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
9.850 +0.150    +1.55%
- Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 5,095
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 9.520 - 9.880
TriSalus Life Sciences 9.850 +0.150 +1.55%

TriSalus Life Sciences Inc Company Profile

 
Get an in-depth profile of TriSalus Life Sciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

106

Equity Type

ORD

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Contact Information

Address 6272 West 91st Avenue
Westminster, 80031
United States
Phone 303 442 1222
Fax -

Top Executives

Name Age Since Title
Steven C. Katz 49 2018 Chief Medical Officer & Chairman of Scientific Advisory Board
Vincent J. Picozzi - - Member of Scientific Advisory Board
Terence Gade - - Member of Scientific Advisory Board
Ripal T. Gandhi - - Member of Scientific Advisory Board
David J. Matlin 62 2023 Independent Director
Mary T. Szela 60 2018 CEO, President & Director
Sean Edward Murphy 71 2021 CFO & Director
Richard D. Carvajal - - Member of Scientific Advisory Board
Alexander Y. Kim - - Member of Scientific Advisory Board
Sirish Kishore - - Member of Scientific Advisory Board
Rahul Sheth - - Member of Scientific Advisory Board
Christopher Crane - - Member of Scientific Advisory Board
Mats L. Wahlstrom 70 2016 Independent Chairman
Michael Pishvaian - 2022 Scientific Advisory Board Member
Andrew C. von Eschenbach 82 2023 Independent Director
George Kelly Martin 65 2023 Independent Director
Arjun M. Desai 42 2023 Independent Director
Anil Singhal 72 2023 Independent Director
Jordan C. Tasse - 2022 Member of Scientific Advisory Board
Sapna Patel - - Member of Scientific Advisory Board
Marlana M. Orloff - - Member of Scientific Advisory Board
Kerry R. Hicks 64 2023 Independent Director
Divya Sridhar - 2022 Member of Scientific Advisory Board
Venu G. Pillarisetty - 2022 Member of Scientific Advisory Board
Liselotte Hyveled 58 2024 Non-Employee Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

TLSI Comments

Write your thoughts about TriSalus Life Sciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Andrew Smith
Andrew Smith Feb 11, 2021 12:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email